Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review

Haider, Masoom A.; Yao, Xiaomei; Loblaw, Andrew; Finelli, Antonio

doi:10.1016/j.clon.2016.05.003

Cited by 37 publications

(23 citation statements)

References 58 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current biomarkers are not sufficient to prevent the overtreatment of PCa. Several serum-based testing (Phi, %p2PSA, and 4KScore), urine-based testing (PCA3) and MRI imaging has shown promising results in terms of diagnosis, localization, risk stratification, and staging of clinically significant PCa [26,27]. However, these promising biomarkers and imaging data are not yet cost-effective enough for routine clinical practice [28].…”

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Hagiwara

Tobisawa

Kaya

et al. 2017

IJMS

View full text Add to dashboard Cite

Wisteria floribunda agglutinin (WFA) preferably binds to LacdiNAc glycans, and its reactivity is associated with tumor progression. The aim of this study to examine whether the serum LacdiNAc carrying prostate-specific antigen–glycosylation isomer (PSA-Gi) and WFA-reactivity of tumor tissue can be applied as a diagnostic and prognostic marker of prostate cancer (PCa). Between 2007 and 2016, serum PSA-Gi levels before prostate biopsy (Pbx) were measured in 184 biopsy-proven benign prostatic hyperplasia patients and 244 PCa patients using an automated lectin-antibody immunoassay. WFA-reactivity on tumor was analyzed in 260 radical prostatectomy (RP) patients. Diagnostic and prognostic performance of serum PSA-Gi was evaluated using area under the receiver-operator characteristic curve (AUC). Prognostic performance of WFA-reactivity on tumor was evaluated via Cox proportional hazards regression analysis and nomogram. The AUC of serum PSA-Gi detecting PCa and predicting Pbx Grade Group (GG) 3 and GG ≥ 3 after RP was much higher than those of conventional PSA. Multivariate analysis showed that WFA-reactivity on prostate tumor was an independent risk factor of PSA recurrence. The nomogram was a strong model for predicting PSA-free survival provability with a c-index ≥0.7. Serum PSA-Gi levels and WFA-reactivity on prostate tumor may be a novel diagnostic and pre- and post-operative prognostic biomarkers of PCa, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Hagiwara

Tobisawa

Kaya

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…The Gleason score is one of the most frequently used histologic grading systems for PCa, and the prognosis of PCa is closely related to the Gleason score 49 ; thus, multicenter studies with a larger number of cases should be conducted to reveal the correlation between the Gleason score and the tissue stiffness of PCa. In addition, a previous study 50 showed that multiparametric MRI (mpMRI) provided the best anatomical and functional imaging of the prostate compared with that of other imaging methods, and a systematic review 51 suggested that mpMRI could be used to trigger a targeted repeat biopsy for prostate cancer diagnosis. Future research should be performed to evaluate the correlations between SWE and mpMRI with histopathology as the gold standard.…”

Section: Discussionmentioning

confidence: 99%

Accuracy of shear wave elastography for the diagnosis of prostate cancer: A meta-analysis

Liang

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Many studies have established the high diagnostic accuracy of shear wave elastography (SWE) for the detection of prostate cancer (PCa); however, its utility remains a subject of debate. This meta-analysis sought to appraise the overall accuracy of SWE for the detection of PCa. A literature search of the PubMed, Embase, Cochrane Library, Web of Science and CNKI (China National Knowledge Infrastructure) databases was conducted. In all of the included studies, the diagnostic accuracy of SWE was compared with that of histopathology, which was used as a standard. Data were pooled, and the sensitivity, specificity, area under the curve (AUC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated to estimate the accuracy of SWE. The pooled sensitivity and specificity for the diagnosis of PCa by SWE were 0.844 (95% confidence interval: 0.696–0.927) and 0.860 (0.792–0.908), respectively. The AUC was 0.91 (0.89–0.94), the PLR was 6.017 (3.674–9.853), and the NLR was 0.182 (0.085–0.389). The DOR was 33.069 (10.222–106.982). Thus, SWE exhibited high accuracy for the detection of PCa using histopathology as a diagnostic standard. Moreover, SWE may reduce the number of core biopsies needed.

show abstract

“…10 Briefly, MEDLINE and EMBASE (from January 1997-April 2014), the Cochrane Library, main guideline websites (from January 2010-October 2013), and main relevant annual meeting abstract websites (from 2011-2014) were searched for relevant existing systematic review-based guidelines, systematic reviews, original studies, and conference abstracts.…”

Section: Literature Searchmentioning

confidence: 99%

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Haider

Yao

Loblaw

et al. 2017

CUAJ

View full text Add to dashboard Cite

Cite as: Can Urol Assoc J 2017;11(1-2):E1-7. http://dx.doi.org/10.5489/cuaj.3968 Published online January 12, 2017 AbstractThis clinical guideline focuses on: 1) the use of multiparametric magnetic resonance imaging (mpMRI) in diagnosing clinically significant prostate cancer (CSPC) in patients with an elevated risk of CSPC and who are biopsy-naïve; and 2) the use of mpMRI in diagnosing CSPC in patients with a persistently elevated risk of having CSPC and who have a negative transrectal ultrasound (TRUS)-guided systematic biopsy.

show abstract

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review

Cited by 37 publications

References 58 publications

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer

Accuracy of shear wave elastography for the diagnosis of prostate cancer: A meta-analysis

Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline

Contact Info

Product

Resources

About